• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

几种最小二乘法的药代动力学参数估计:扩展最小二乘法的优越性

Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

作者信息

Sheiner L B, Beal S L

出版信息

J Pharmacokinet Biopharm. 1985 Apr;13(2):185-201. doi: 10.1007/BF01059398.

DOI:10.1007/BF01059398
PMID:4057057
Abstract

The precision of pharmacokinetic parameter estimates from several least squares parameter estimation methods are compared. The methods can be thought of as differing with respect to the way they weight data. Three standard methods, Ordinary Least Squares (OLS-equal weighting), Weighted Least Squares with reciprocal squared observation weighting [WLS(y-2)], and log transform OLS (OLS(ln))--the log of the pharmacokinetic model is fit to the log of the observations--are compared along with two newer methods, Iteratively Reweighted Least Squares with reciprocal squared prediction weighting (IRLS,(f-2)), and Extended Least Squares with power function "weighting" (ELS(f-xi)--here xi is regarded as an unknown parameter). The values of the weights are more influenced by the data with the ELS(f-xi) method than they are with the other methods. The methods are compared using simulated data from several pharmacokinetic models (monoexponential, Bateman, Michaelis-Menten) and several models for the observation error magnitude. For all methods, the true structural model form is assumed known. Each of the standard methods performs best when the actual observation error magnitude conforms to the assumption of the method, but OLS is generally least perturbed by wrong error models. In contrast, WLS(y-2) is the worst of all methods for all error models violating its assumption (and even for the one that does not, it is out performed by OLS(ln)). Regarding the newer methods, IRLS(f-2) improves on OLS(ln), but is still often inferior to OLS. ELS(f-xi), however, is nearly as good as OLS (OLS is only 1-2% better) when the OLS assumption obtains, and in all other cases ELS(f-xi) does better than OLS. Thus, ELS(f-xi) provides a flexible and robust method for estimating pharmacokinetic parameters.

摘要

比较了几种最小二乘参数估计方法所得药代动力学参数估计值的精度。这些方法可以被认为在加权数据的方式上有所不同。将三种标准方法,即普通最小二乘法(OLS - 等权重)、采用倒数平方观测加权的加权最小二乘法[WLS(y - 2)]以及对数变换OLS(OLS(ln))——药代动力学模型的对数拟合观测值的对数——与两种较新的方法进行了比较,这两种新方法分别是采用倒数平方预测加权的迭代加权最小二乘法(IRLS,(f - 2))和具有幂函数“加权”的扩展最小二乘法(ELS(f - xi)——这里xi被视为未知参数)。与其他方法相比,ELS(f - xi)方法中权重的值受数据的影响更大。使用来自几种药代动力学模型(单指数模型、贝特曼模型、米氏模型)以及几种观测误差大小模型的模拟数据对这些方法进行了比较。对于所有方法,假定真实的结构模型形式是已知的。当实际观测误差大小符合该方法的假设时,每种标准方法的表现最佳,但OLS通常受错误误差模型的干扰最小。相比之下,对于所有违反其假设的误差模型,WLS(y - 2)是所有方法中表现最差的(甚至对于不违反其假设的误差模型,它也不如OLS(ln))。关于较新的方法,IRLS(f - 2)比OLS(ln)有所改进,但仍常常不如OLS。然而,当OLS假设成立时,ELS(f - xi)几乎与OLS一样好(OLS仅好1 - 2%),并且在所有其他情况下,ELS(f - xi)的表现都优于OLS。因此,ELS(f - xi)为估计药代动力学参数提供了一种灵活且稳健的方法。

相似文献

1
Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.几种最小二乘法的药代动力学参数估计:扩展最小二乘法的优越性
J Pharmacokinet Biopharm. 1985 Apr;13(2):185-201. doi: 10.1007/BF01059398.
2
Pharmacokinetic parameter estimations by minimum relative entropy method.基于最小相对熵法的药代动力学参数估计
J Pharmacokinet Biopharm. 1995 Oct;23(5):479-94. doi: 10.1007/BF02353470.
3
Evaluation of nonlinear regression with extended least squares: simulation study.扩展最小二乘法的非线性回归评估:模拟研究
J Pharm Sci. 1985 Dec;74(12):1327-30. doi: 10.1002/jps.2600741215.
4
Evaluation of objective functions for estimation of kinetic parameters.用于估计动力学参数的目标函数评估。
Med Phys. 2006 Feb;33(2):342-53. doi: 10.1118/1.2135907.
5
An evaluation of extended vs weighted least squares for parameter estimation in physiological modeling.生理建模中参数估计的扩展最小二乘法与加权最小二乘法评估。
J Biomed Inform. 2001 Oct;34(5):348-64. doi: 10.1006/jbin.2001.1033.
6
A note on confidence intervals with extended least squares parameter estimates.关于扩展最小二乘参数估计的置信区间的注释。
J Pharmacokinet Biopharm. 1987 Feb;15(1):93-8. doi: 10.1007/BF01062941.
7
Improving uncertainty analysis in kinetic evaluations using iteratively reweighted least squares.使用迭代重加权最小二乘法提高动力学评估中的不确定性分析。
Environ Toxicol Chem. 2011 Oct;30(10):2363-71. doi: 10.1002/etc.630. Epub 2011 Aug 24.
8
Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.扩展最小二乘非线性回归:个体药代动力学数据分析中“权重选择”问题的一种可能解决方案。
J Pharmacokinet Biopharm. 1984 Oct;12(5):545-58. doi: 10.1007/BF01060132.
9
A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment.精神分裂症治疗资源消耗分析中处理偏态分布成本变量方法的比较。
J Ment Health Policy Econ. 2002 Mar;5(1):21-31.
10
An analysis program MULTI(ELS) based on extended nonlinear least squares method for microcomputers.一种基于扩展非线性最小二乘法的微机分析程序MULTI(ELS)。
J Pharmacobiodyn. 1986 Feb;9(2):161-73.

引用本文的文献

1
The Effects of Additional Local-Mixing Compartments in the DISST Model-Based Assessment of Insulin Sensitivity.在基于 DISST 模型的胰岛素敏感性评估中附加局部混合隔室的效果。
J Diabetes Sci Technol. 2022 Sep;16(5):1196-1207. doi: 10.1177/19322968211021602. Epub 2021 Jun 11.
2
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.组成型细胞增殖调控蛋白磷酸酶 2A 抑制剂(CIP2A)介导 EGFR 激活突变型 NSCLC 细胞系对厄洛替尼的耐药性。
Cells. 2021 Mar 24;10(4):716. doi: 10.3390/cells10040716.
3
Evidence for an effect of receptor density on ligand occupancy and agonist EC.

本文引用的文献

1
Investigation of the effect of data error in the analysis of biological tracer data.生物示踪数据分析中数据误差的影响研究。
Biophys J. 1967 Nov;7(6):903-11. doi: 10.1016/S0006-3495(67)86628-1. Epub 2008 Dec 31.
2
Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.群体药代动力学参数估计方法的评估。II. 双指数模型与实验药代动力学数据
J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. doi: 10.1007/BF01061030.
3
Some suggestions for measuring predictive performance.
受体密度对配体占有率和激动剂 EC 的影响的证据。
Sci Rep. 2019 Dec 13;9(1):19111. doi: 10.1038/s41598-019-55361-x.
4
Citalopram inhibits platelet function independently of SERT-mediated 5-HT transport.西酞普兰抑制血小板功能不依赖 SERT 介导体 5-HT 转运。
Sci Rep. 2018 Feb 22;8(1):3494. doi: 10.1038/s41598-018-21348-3.
5
Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.新型基于生理的母婴药代动力学模型的建立II:被动胎盘通透性药物模型的验证
Drug Metab Dispos. 2017 Aug;45(8):939-946. doi: 10.1124/dmd.116.073957. Epub 2017 Jan 3.
6
Estimating limits for natural human embryo mortality.估算人类自然胚胎死亡率的限度。
F1000Res. 2016 Aug 26;5:2083. doi: 10.12688/f1000research.9479.1. eCollection 2016.
7
Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought Process.探讨运用机制模型生成体内/体外相关性:思维过程之旅。
AAPS J. 2016 Sep;18(5):1144-1158. doi: 10.1208/s12248-016-9930-1. Epub 2016 Jun 16.
8
A strategy for residual error modeling incorporating scedasticity of variance and distribution shape.一种结合方差的异方差性和分布形状的残差误差建模策略。
J Pharmacokinet Pharmacodyn. 2016 Apr;43(2):137-51. doi: 10.1007/s10928-015-9460-y. Epub 2015 Dec 17.
9
Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.伐尼克兰对成年吸烟者尼古丁渴望影响的药代动力学-药效学建模
Nicotine Tob Res. 2015 Jan;17(1):106-13. doi: 10.1093/ntr/ntu154. Epub 2014 Aug 21.
10
Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data.建立利福平诱导的 CYP3A4 激活动力学模型,用于从体外数据预测临床药物相互作用。
PLoS One. 2013 Sep 24;8(9):e70330. doi: 10.1371/journal.pone.0070330. eCollection 2013.
一些关于衡量预测性能的建议。
J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12. doi: 10.1007/BF01060893.
4
Fitting of enzyme kinetic data without prior knowledge of weights.在不预先了解权重的情况下对酶动力学数据进行拟合。
Biochem J. 1981 Mar 1;193(3):1005-8. doi: 10.1042/bj1931005.
5
Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.群体药代动力学参数估算方法的评估。I. 米氏模型:常规临床药代动力学数据。
J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053.
6
Nonparametric pharmacokinetic calculations: one-compartment open model.非参数药代动力学计算:一室开放模型。
J Pharm Sci. 1983 Oct;72(10):1218-21. doi: 10.1002/jps.2600721030.
7
Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.群体药代动力学参数估计方法的评价。III. 单指数模型:常规临床药代动力学数据
J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19. doi: 10.1007/BF01061870.
8
Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.扩展最小二乘非线性回归:个体药代动力学数据分析中“权重选择”问题的一种可能解决方案。
J Pharmacokinet Biopharm. 1984 Oct;12(5):545-58. doi: 10.1007/BF01060132.
9
Investigation of the effect of data error in the analysis of biological tracer data from three compartment systems.三室系统生物示踪剂数据分析中数据误差影响的研究
J Theor Biol. 1969 May;23(2):218-31. doi: 10.1016/0022-5193(69)90038-1.
10
Statistical considerations in the estimation of enzyme kinetic parameters by the direct linear plot andother methods.通过直接线性作图法及其他方法估算酶动力学参数时的统计学考量
Biochem J. 1974 Jun;139(3):721-30. doi: 10.1042/bj1390721.